USD 150 million to scale DEXTER the surgical sobot across the US
19.11.2025
Distalmotion, the Swiss developer of the surgical robot DEXTER, has secured USD 150 million in a Series G financing round to expand its footprint across the United States. The funding, led by Revival Healthcare Capital and supported by existing investors, will accelerate the commercial adoption of DEXTER, particularly in the rapidly growing Ambulatory Surgery Center (ASC) market, and support ongoing clinical and product development initiatives.
DEXTER is a soft tissue robotic surgery system designed to simplify operations and extend the benefits of wristed robotics to any operating room (OR). Its compact, mobile design allows integration into ORs of all sizes without modifications, and it can easily move between rooms, maximizing efficiency. The sterile console supports flexible surgical workflows, facilitates seamless transitions between laparoscopic and robotic techniques, and enhances communication among surgical teams. Since its introduction, DEXTER has been successfully used in clinical settings across Europe and the US, with nearly 3,000 patients treated to date.
The USD 150 million Series G round positions Distalmotion to scale its US operations, with a particular focus on outpatient surgical sites. The ASC market continues to grow rapidly, driven by a shift toward efficient, cost-effective outpatient procedures, making it a strategic priority for the company.
Alongside the financing announcement, Distalmotion named Chas McKhann as Executive Chairman of the Board of Directors. With over 25 years of experience in MedTech and life sciences, McKhann has a proven track record in scaling medical device companies and driving commercial growth. He previously led Apollo Endosurgery and Silk Road Medical, achieving significant sales growth and successful exits for both publicly traded companies. His appointment reinforces Distalmotion’s commitment to establishing DEXTER as a leading robotic surgery solution in the ASC sector.
With this latest funding and leadership reinforcement, Distalmotion is ready to expand DEXTER’s presence in the US, offering hospitals and outpatient centers greater access to advanced robotic surgical capabilities.
The company was ranked among the Top100 Swiss Startups and Top100 Scale-ups, participated in Venture Leaders, and won the final stage of Venture Kick.
Distalmotion co-founder Michael Friedrich at the Venture Leaders China kick-off in 2018
The USD 150 million Series G round positions Distalmotion to scale its US operations, with a particular focus on outpatient surgical sites. The ASC market continues to grow rapidly, driven by a shift toward efficient, cost-effective outpatient procedures, making it a strategic priority for the company.
Alongside the financing announcement, Distalmotion named Chas McKhann as Executive Chairman of the Board of Directors. With over 25 years of experience in MedTech and life sciences, McKhann has a proven track record in scaling medical device companies and driving commercial growth. He previously led Apollo Endosurgery and Silk Road Medical, achieving significant sales growth and successful exits for both publicly traded companies. His appointment reinforces Distalmotion’s commitment to establishing DEXTER as a leading robotic surgery solution in the ASC sector.
With this latest funding and leadership reinforcement, Distalmotion is ready to expand DEXTER’s presence in the US, offering hospitals and outpatient centers greater access to advanced robotic surgical capabilities.
The company was ranked among the Top100 Swiss Startups and Top100 Scale-ups, participated in Venture Leaders, and won the final stage of Venture Kick.
Distalmotion co-founder Michael Friedrich at the Venture Leaders China kick-off in 2018